Core Viewpoint - Bon Natural Life Limited has entered into a 36-month exclusive cooperation agreement with Beijing Huahai Keyuan for the distribution of its patented postbiotic hypoglycemic ingredients, aiming to penetrate the global blood sugar health market with a contract value of 32 million US dollars [1]. Company Summary - Bon Natural Life Limited is a leading provider of bio-ingredient solutions in the natural, health, and personal care industry, focusing on innovative hypoglycemic solutions [1][5]. - The company holds a patent for a postbiotic hypoglycemic ingredient that effectively regulates blood sugar levels, particularly post-meal glucose spikes, and is characterized by its safety and ease of use [2]. Industry Summary - The postprandial blood glucose control market is valued at over 30 billion US dollars and is experiencing a compound annual growth rate of 7.5% [3]. - The company anticipates significant advancements in its hypoglycemic product line over the next 2-3 years, which is expected to drive sales growth and enhance investment value [4].